4588
Oncolys BioPharma Inc.
オンコリスバイオファーマ
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Non-consolidated
Key metrics
Revenue(thousand JPY)
Dec 2021
642,494
Dec 2022
976,182
Dec 2023
63,038
Dec 2024
31,384
Dec 2025
28,546
Operating profit(thousand JPY)
Dec 2021
-1,454,554
Dec 2022
-1,204,506
Dec 2023
-1,929,986
Dec 2024
-1,681,403
Dec 2025
-2,024,068
Operating profit margin(%)
Dec 2021
-226.39
Dec 2022
-123.39
Dec 2023
-3,061.62
Dec 2024
-5,357.52
Dec 2025
-7,090.55
Profit before tax(thousand JPY)
Dec 2021
-1,611,714
Dec 2022
-1,146,005
Dec 2023
-1,935,578
Dec 2024
-1,681,015
Dec 2025
-2,054,016
Profit(thousand JPY)
Dec 2021
-1,615,439
Dec 2022
-1,148,938
Dec 2023
-1,938,505
Dec 2024
-1,684,778
Dec 2025
-2,058,049
Total assets(thousand JPY)
Dec 2021
4,291,876
Dec 2022
2,650,959
Dec 2023
2,040,598
Dec 2024
3,198,858
Dec 2025
4,555,879
Cash and cash equivalents(thousand JPY)
Dec 2021
3,209,635
Dec 2022
1,466,201
Dec 2023
1,287,763
Dec 2024
2,165,918
Dec 2025
3,429,561
Cash flows from operating activities(thousand JPY)
Dec 2021
-1,741,827
Dec 2022
-1,717,135
Dec 2023
-1,336,922
Dec 2024
-2,020,088
Dec 2025
-1,940,866
Cash flows from investing activities(thousand JPY)
Dec 2021
-942
Dec 2022
20,117
Dec 2023
-5,392
Dec 2024
-4,705
Dec 2025
-7,583
Cash flows from financing activities(thousand JPY)
Dec 2021
3,091,384
Dec 2022
-113,830
Dec 2023
1,142,542
Dec 2024
2,879,444
Dec 2025
3,221,897
Return on equity(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Equity ratio(%)
Dec 2021
83.6
Dec 2022
81.2
Dec 2023
71.5
Dec 2024
85.8
Dec 2025
87.6
Earnings per share(JPY per share)
Dec 2021
-95.5
Dec 2022
-66.31
Dec 2023
-108.92
Dec 2024
-77.17
Dec 2025
-80
Net assets per share(JPY per share)
Dec 2021
206.86
Dec 2022
124.2
Dec 2023
74.35
Dec 2024
110.4
Dec 2025
136.38
Dividend per share(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Payout ratio(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.